Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

CAR-T

- PMLiVE

CAR-Ts take centre stage as ASH18 comes to a close

Candidates from Allogene, Legend Biotech and Novartis were among the highlights

- PMLiVE

BCMA in the spotlight as ASH abstracts drop

Updated results from promising CAR-T therapies are expected

- PMLiVE

Encouraging data for GenSight’s blinding retinal disease gene therapy

Better results after April's setback

- PMLiVE

Orchard plans IPO as gene therapy pipeline advances

UK biotech seeks funds for expanded rare disease portfolio

- PMLiVE

EMA to review Bluebird’s blood disorder gene therapy

LentiGlobin could free patients of regular blood transfusions

- PMLiVE

Novartis’ CAR-T Kymriah gets green light in England

Speedy decision contrasts with NICE's 'no' to rival Yescarta in larger adult DLBCL population

- PMLiVE

Armoured CAR ‘could overwhelm solid tumour resistance’

Eureka Therapeutics and Memorial Sloan Kettering approach shows promise

- PMLiVE

Sangamo bulks up in cell therapy with TxCell acquisition

Hopes to start cell-based immunotherapy trials next year

- PMLiVE

Pfizer enters late-stage haemophilia B gene therapy trial

Race is on to free patients of regular injections

AstraZeneca AZ

AZ makes gene therapy move with 4DMT alliance

The new partnership will focus on creating an AAV for lung disease

- PMLiVE

Axovant licenses another gene therapy as new strategy beds in

Group pursues gene therapy strategy

Training the next generation of biotech leaders

Blue Latitude Health speaks to Dr Ivan Wall, Reader in Cell & Gene Therapy Bioprocessing at University College London, to find out about the future of cell and gene therapy,...

Blue Latitude Health

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links